These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9712438)

  • 21. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
    Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
    Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
    Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II).
    Baretton GB; Vogt M; Müller C; Diebold J; Schneiderbanger K; Schmidt M; Löhrs U
    Scand J Gastroenterol; 1996 May; 31(5):481-9. PubMed ID: 8734346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features.
    Lee CC; Yamamoto S; Morimura K; Wanibuchi H; Nishisaka N; Ikemoto S; Nakatani T; Wada S; Kishimoto T; Fukushima S
    Cancer; 1997 Feb; 79(4):780-9. PubMed ID: 9024716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
    Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
    Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis.
    Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Okamune A; Sugiura S; Noguchi N; Yamamoto E
    J Oral Pathol Med; 2011 Oct; 40(9):693-8. PubMed ID: 21501231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
    Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
    Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.
    Sauter G; Deng G; Moch H; Kerschmann R; Matsumura K; De Vries S; George T; Fuentes J; Carroll P; Mihatsch MJ
    Am J Pathol; 1994 Apr; 144(4):756-66. PubMed ID: 8160775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization.
    Hopman AH; Moesker O; Smeets AW; Pauwels RP; Vooijs GP; Ramaekers FC
    Cancer Res; 1991 Jan; 51(2):644-51. PubMed ID: 1985781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.
    Kuczyk MA; Serth J; Hervatin C; Arndt H; Derendorf L; Thon WF; Jonas U
    World J Urol; 1994; 12(6):345-51. PubMed ID: 7881474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis.
    Poddighe PJ; Bringuier PP; Vallinga M; Schalken JA; Ramaekers FC; Hopman AH
    J Pathol; 1996 Jun; 179(2):169-76. PubMed ID: 8758209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Ogura K; Fukuzawa S; Habuchi T; Ogawa O; Yoshida O
    Int J Urol; 1997 Nov; 4(6):561-6. PubMed ID: 9477184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization.
    Hopman AH; Poddighe PJ; Smeets AW; Moesker O; Beck JL; Vooijs GP; Ramaekers FC
    Am J Pathol; 1989 Dec; 135(6):1105-17. PubMed ID: 2688431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study on aberrations of chromosome 17 and proliferating cell fraction in lung cancer.
    Lee KJ; Lee MS; Kim JO; Kim SY
    J Korean Med Sci; 1993 Aug; 8(4):271-80. PubMed ID: 7911024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between different p53 expression patterns and chromosome 17 imbalances in pancreatic ductal adenocarcinoma based on tissue microarray analysis.
    Tsiambas E; Kravvaritis C; Tsounis D; Salemis NS; Niotis A; Niotis TH; Rigopoulos DN; Karameris A; Athanasiou AE; Patsouris E; Karakitsos P
    J BUON; 2010; 15(1):94-100. PubMed ID: 20414934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression.
    Li X; Tsuji T; Wen S; Mimura Y; Sasaki K; Shinozaki F
    Cancer; 1997 Jun; 79(12):2314-9. PubMed ID: 9191518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic analyses of hepatocellular carcinoma by in situ hybridization with a chromosome-specific DNA probe.
    Kimura H; Kagawa K; Deguchi T; Nakajima T; Kakusui M; Ohkawara T; Katagishi T; Okanoue T; Kashima K; Ashihara T
    Cancer; 1996 Jan; 77(2):271-7. PubMed ID: 8625234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer.
    Moch H; Sauter G; Mihatsch MJ; Gudat F; Epper R; Waldman FM
    Hum Pathol; 1994 Dec; 25(12):1346-51. PubMed ID: 8001930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.